Wolfgang Landgraf
7PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Nov 03, 2025
Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.Wolfgang Landgraf, David R Owens, Brian M Frier
|Jun 15, 2024
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis.Wolfgang Landgraf, David R Owens, Brian M Frier
|Oct 20, 2023
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.Wolfgang Landgraf, David R Owens, Brian M Frier
|Jun 14, 2023
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.Robert Ritzel, Sujoy Ghosh, Rifat Emral
|Apr 22, 2020
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.Geremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak
|Oct 15, 2019
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.Wolfgang Landgraf, David R Owens, Brian M Frier
Pageof 2
